ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1227

Reduction in Peripheral CD19+ CD27- Naïve B Cells Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis Receiving Combined Treatment with Methotrexate and TNF Inhibitors

Borja Hernandez-Breijo1, Chamaida Plasencia2, Victoria Navarro-Compán3, Israel Nieto-Gañán4, Cristina Sobrino5, Ana Martínez-Feito6, Carlota García-Hoz4, Paloma Lapuente-Suanzes4, Javier Bachiller-Corral7, Gema Bonilla2, Cristina Pijoán-Moratalla7, Garbiñe Roy4, Mónica Vázquez7, Alejandro Balsa2, Luisa M Villar4, Dora Pascual-Salcedo8 and Eulalia Rodríguez-Martín4, 1Immuno-rheumatology Research group. IdiPAZ. La Paz University Hospital, Madrid, Spain, 2Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, 3Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, 4Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain, 5Hospital Ramón y Cajal-IRYCIS, Madrid, Spain, 6Hospital Unversitario La Paz- idipaz, Madrid, Spain, 7Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 8Hospital Universitario La Paz- Idipaz, Madrid, Spain

Meeting: ACR Convergence 2020

Keywords: B-Lymphocyte, rheumatoid arthritis, TNF-blocking Antibody

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Biological therapies, as TNF inhibitors (TNFi) are increasing remission rates in rheumatoid arthritis (RA) patients although these are still limited. This study aims to explore whether TNFi modulate peripheral blood mononuclear cells (PBMC) after 6 months (m) of treatment and to identify a cellular profile associated with clinical remission (REM) in patients with RA.

Methods: A prospective and observational bi-center study including 78 patients with RA treated with standard doses of their first TNFi and followed-up during 6m was carried out. All included patients fulfilled the ACR/EULAR 2010 classification criteria for RA, were adults, with moderate or high disease activity (DAS28 >3.2). PBMC were analysed by flow-cytometry at the baseline and 6m. Clinical activity at baseline and after 6m was assessed by DAS28, establishing DAS28≤2.6 as the criteria for REM. Depending on data distribution, comparisons were conducted using unpaired t, Mann-Whitney U or Fisher’s exact tests. The association between REM and the percentage of change (Δ, 6m-0m) within each PBMC subset was evaluated by uni- and multi-variable logistic regression. The presence of interactions with covariates (age, sex, disease duration, RF, ACPA, smoking habit, body mass index, baseline DAS28 and concomitant methotrexate (MTX)) was tested, stratifying the results if this was significant (p< 0.05). In case of no interaction, the model was later adjusted for these covariates.

Results: After 6m of TNFi treatment, 37% patients achieved REM. Univariable analyses (odds ratio; 95% CI; p-value) were performed to investigate the association between REM and the baseline variables. A significant association was found for lower baseline DAS28 (OR: 0.28; 95% CI: 0.19-0.51; p< 0.001). Associations of REM with other baseline patients’ characteristics, such as for age (OR: 0.97; 95% CI: 0.94-1.01; p=0.1), RF positivity (OR: 2.50; 95% CI: 0.73-8.50; p=0.1) and ACPA positivity (OR: 3.91; 95% CI: 0.80-19.07; p=0.09), were found, although not significant. Therefore, further analyses were adjusted by age, RF, ACPA and baseline DAS28. In addition, a significant association were found for reducing the percentage of naïve B cells (OR: 0.85; 95% CI: 0.73-0.99; p=0.04). A significant interaction between the change in the percentage of naïve B cells and the use of concomitant MTX was identified (Wald chi-square value=4.56; p=0.03), for the outcome of achievement of REM. Therefore, further analyses about the association between the change in the percentage of naïve B cells and REM were stratified according to the use of concomitant MTX. No significant interactions with other variables were found.

A reduction in the percentage of naïve B cells after 6m of TNFi treatment was associated with achieving REM, mainly in patients who received concomitant MTX (OR: 0.58; 95% CI: 0.38-0.90; p=0.015). However, no association was found for patients who did not received concomitant MTX (OR: 0.78; 95% CI: 0.45-1.35; p=0.4).

Conclusion: A reduction of naïve B cells was associated with the achievement of REM by TNFi therapy, mainly in patients who received concomitant methotrexate. Our results suggest that naïve B cells may be useful as a marker of REM in patients with RA cotreated with TNFi and MTX.

Baseline characteristics of patients included in the study, stratified by remission at 6 months of TNFi treatment The table shows mean±SD, median (IQR) or absolute number (percentage) for all patients included (n=78). RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies; DAS28, Disease Activity Score-28; csDMARD, conventional synthetic disease-modifying anti-rheumatic drug; MTX, methotrexate; OD, other conventional synthetic disease-modifying anti-rheumatic drugs than methotrexate. The differences between groups were analysed considering p-value < 0.05 as statistically significant result.


Disclosure: B. Hernandez-Breijo, None; C. Plasencia, None; V. Navarro-Compán, Novartis Pharma, 1, 5, 8, AbbVie Inc., 5, 8, Eli Lilly and Company, 5, 8, Pfizer Inc., 5, UCB, 5, 8; I. Nieto-Gañán, None; C. Sobrino, None; A. Martínez-Feito, None; C. García-Hoz, None; P. Lapuente-Suanzes, None; J. Bachiller-Corral, None; G. Bonilla, None; C. Pijoán-Moratalla, None; G. Roy, None; M. Vázquez, None; A. Balsa, BMS, 9; L. Villar, None; D. Pascual-Salcedo, None; E. Rodríguez-Martín, None.

To cite this abstract in AMA style:

Hernandez-Breijo B, Plasencia C, Navarro-Compán V, Nieto-Gañán I, Sobrino C, Martínez-Feito A, García-Hoz C, Lapuente-Suanzes P, Bachiller-Corral J, Bonilla G, Pijoán-Moratalla C, Roy G, Vázquez M, Balsa A, Villar L, Pascual-Salcedo D, Rodríguez-Martín E. Reduction in Peripheral CD19+ CD27- Naïve B Cells Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis Receiving Combined Treatment with Methotrexate and TNF Inhibitors [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/reduction-in-peripheral-cd19-cd27-naive-b-cells-is-associated-with-clinical-remission-in-patients-with-rheumatoid-arthritis-receiving-combined-treatment-with-methotrexate-and-tnf-inhibitors/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduction-in-peripheral-cd19-cd27-naive-b-cells-is-associated-with-clinical-remission-in-patients-with-rheumatoid-arthritis-receiving-combined-treatment-with-methotrexate-and-tnf-inhibitors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology